CCL22 and neoplasm: Co-expression of CCR4 improved the homing ability of anti-CD30 CAR-T cells to Hodgkin tumor sites by enhancing their migration toward CCR4 ligands CCL17 and CCL22, which are highly expressed in the tumor microenvironment (182).